<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00851773</url>
  </required_header>
  <id_info>
    <org_study_id>NN9535-3633</org_study_id>
    <secondary_id>2008-006325-13</secondary_id>
    <nct_id>NCT00851773</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects</brief_title>
  <official_title>A Randomised, Double Blind, Placebo-controlled, Parallel-group, Multiple Doses, Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics Profiles of NN9535 in Healthy Male Japanese and Caucasian Subjects After Weekly Subcutaneous Injections.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. The aim of this clinical trial is to assess and compare
      the safety and tolerability, as assessed by adverse events after multiple subcutaneous doses
      of NN9535 in healthy male Japanese and Caucasian subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>at all scheduled visits (2 - 14) following screening</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of hypoglycaemic episodes</measure>
    <time_frame>at all scheduled visits (2 - 14) following screening</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs (blood pressure and pulse)</measure>
    <time_frame>at all scheduled visits (2 - 14) including screening (visit 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG (electrocardiogram)</measure>
    <time_frame>at all scheduled visits (2 - 14) including screening (visit 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Haematology</measure>
    <time_frame>at all scheduled visits (2 - 14) including screening (visit 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemistry</measure>
    <time_frame>at all scheduled visits (2 - 14) including screening (visit 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinalysis</measure>
    <time_frame>at all scheduled visits (2 - 14) including screening (visit 1)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calcitonin</measure>
    <time_frame>at screening (visit 1) and at visits 2, 9 and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody development against N9535</measure>
    <time_frame>at visits 2 and 14</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>F1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>F2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>F3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>F4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>F5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>0.1 mg once weekly, s.c. injection</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>0.2 mg once weekly, s.c. injection</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>0.4 mg once weekly, s.c. injection</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection</description>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>semaglutide</intervention_name>
    <description>0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, 1.2 mg once weekly for 6 weeks, s.c. injection</description>
    <arm_group_label>E</arm_group_label>
    <other_name>NN9535</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>0.1 mg once weekly, s.c. injection</description>
    <arm_group_label>F1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>0.2 mg once weekly, s.c. injection</description>
    <arm_group_label>F2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>0.4 mg once weekly, s.c. injection</description>
    <arm_group_label>F3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection</description>
    <arm_group_label>F4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, followed by 1.2 mg once weekly injections for 6 weeks, s.c. injection</description>
    <arm_group_label>F5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For Caucasian or Japanese volunteers the following applies:

          -  Informed consent obtained before any trial-related activities

          -  Body weight between 54 and 90 kg (both inclusive)

          -  Body mass index (BMI) between 18.5 and 24.9 kg/m2 (both inclusive)

          -  HbA1c below 6.0 %

          -  Subjects who are considered to be generally healthy based on assessment of medical
             history, physical examination and clinical laboratory data at screening, as judged by
             the Investigator

          -  Subjects who are sexually active and have partners who are or could be pregnant are
             willing and required to use a barrier method of contraception (e.g. condom) for the
             duration of the study and for 90 days following the last dose of study medication

          -  Japanese passport holder, Japanese-born parents, lived outside Japan for 5 years or
             less

        Exclusion Criteria:

          -  Any clinical laboratory values deviating from or outside the laboratory reference
             range unless considered not to be clinically significant by the investigator

          -  Any abnormal ECG findings at the screening, considered to be clinically significant by
             the Investigator

          -  Presence or history of diabetes, cancer or any clinically significant cardiac,
             respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological,
             dermatological, venereal, haematological, neurological, or psychiatric diseases or
             disorders, considered to be clinically significant by the Investigator

          -  Previous randomised in this trial (not applicable for stand-by volunteers)

          -  Blood pressure in supine position at the screening, after resting for 5 min, and in
             the standing position after standing for 1 min, consistently outside the ranges 90 -
             140 mmHg systolic or 40 - 90 mmHg diastolic

          -  Heart rate in supine position at the screening, after resting for 5 min, consistently
             above 100 beats/min

          -  Alcohol intake within 48 hours prior to the screening and admission (examined by
             alcohol breath test)

          -  Hepatitis B surface antigen, Hepatitis C antibodies or Human Immunodeficiency Virus
             (HIV) antibodies positive

          -  History of significant allergy or hypersensitivity

          -  Known or suspected allergy to trial product or related products

          -  History of drug or alcohol abuse (alcohol abuse is defined as intake of more than 21
             units (U) weekly: One unit of alcohol equals 1/2 pint (approximately 250 mL) of beer
             or lager, or one glass of wine or Japanese sake, or 1/6 gill (approximately 20 mL) of
             spirits)

          -  Subjects who smoke more than 10 cigarettes, or the equivalent, per day or is unwilling
             to refrain from smoking whenever required for the trial procedure

          -  Use of prescription drugs within 3 weeks prior to dosing, non-prescription drugs
             within 1 week prior to dosing except for vitamins, minerals and nutritional
             supplements

          -  Received any investigational drug within 12 weeks prior to the planned first dosing

          -  Subjects who have taken part in strenuous exercise within 48 hours prior to first
             dosing, due to interference with the hepatic microsomal monooxygenase system. The
             Investigator or Sub-Investigator will evaluate whether strenuous exercise has been
             undertaken

          -  Loss of more than 400 mL blood in total within the last 12 weeks or more than 200 mL
             blood in total within the last 4 weeks prior to first dosing

          -  Subjects with a first-degree relative with diabetes mellitus

          -  Mental incapacity, unwillingness or language barriers precluding adequate
             understanding or cooperation

          -  Possibility that the subject will not comply with the protocol

          -  Subjects who in the opinion of the Investigator or Sub-Investigator should not
             participate in the trial

          -  Subjects with known history of either Type 1 or Type 2 diabetes mellitus are excluded
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>London SW</city>
        <zip>17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 25, 2009</study_first_submitted>
  <study_first_submitted_qc>February 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2009</study_first_posted>
  <last_update_submitted>February 20, 2015</last_update_submitted>
  <last_update_submitted_qc>February 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

